Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(11):825; doi:10.1093/jnci/djk234
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Savage, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Savage, L.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

MEMO TO THE MEDIA

Press Release

Cisplatin is More Effective than Carboplatin for Treating Non–Small-Cell Lung Cancer

Liz Savage

jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute

The first 10% of the full text of this article appears below.

Some patients with advanced non–small-cell lung cancer (NSCLC) have slightly higher survival rates when treated with the chemotherapy drug cisplatin than another platinum-based drug, carboplatin, according to a study in the June 6 Journal of the National Cancer Institute. The authors conclude that cisplatin chemotherapy should remain the standard of care for these patients.

Recent randomized studies have shown that the addition of platinum-based drugs to standard chemotherapy improves patient . . . [Full Text of this Article]

Note to Reporters:


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Cisplatin Versus Carboplatin for Patients With Metastatic Non–Small-Cell Lung Cancer—An Old Rivalry Renewed
Christopher G. Azzoli, Mark G. Kris, and David G. Pfister
J Natl Cancer Inst 2007 99: 828-829. [Extract] [Full Text] [PDF]

Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis
Andrea Ardizzoni, Luca Boni, Marcello Tiseo, Frank V. Fossella, Joan H. Schiller, Marianne Paesmans, Davorin Radosavljevic, Adriano Paccagnella, Petr Zatloukal, Paola Mazzanti, Donald Bisset, and Rafael Rosell
J Natl Cancer Inst 2007 99: 847-857. [Abstract] [Full Text] [PDF]